EN DE

JLK, Inc (322510) Fair Value & Analysis

Industrials · KR · Market cap 127B KRW

JI JLK, Inc 322510 · KQ
Price5,500 KRW
Fair Value1,370 KRW
Upside-75.1%
Quality27/100
Watch JLK, Inc for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 0.0% net margin
Low debt · negative free cash flow
Trails peers (2/8)
Narrow moat 10/100
Evidence: Low Range 1,028 KRW – 1,713 KRW Share as image

Fair value as of: Aug 13, 2026

From 2 valuation models · updated today

Fair value updated Aug 13, 2026, revised from 651.67 KRW to 1,370 KRW (+110.2%) since Jul 21, 2026. Share price +22.1% over the past month.

Below-average quality, and screening another 75% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (1,713 KRW). The favourable scenario is already priced in.
  • Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

29,002 KRW 2,417 KRW Fair Value 1,370 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 2,417 KRW – 29,002 KRW · fair‑value band 1,028 KRW – 1,713 KRW · the 5,500 KRW price screens above the 1,370 KRW fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

JLK, Inc (322510) currently trades at 5,500 KRW, while our model-based Fair Value estimate is 1,370 KRW, implying the stock looks roughly 75.1% overvalued today. The Quality Score stands at 27/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at 3.3B KRW. Revenue declined 15.1% year over year. It earns a return on equity of -33.5%. Net debt stands at 26.2B KRW. Fundamentals as of Aug 13, 2026

Our scenario range runs from 1,028 KRW (bear case) to 1,713 KRW (bull case); at 5,500 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 46% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at 11% fair-value upside, at -75%, 322510 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
P/B Multiple 1,032 KRW 1,376 KRW 1,720 KRW 55
NCAV (Graham) 809.20 KRW 1,084 KRW 1,618 KRW 50
All 2 models by family
Multiples
P/B Multiple 1,032 KRW 1,376 KRW 1,720 KRW 55
Asset-Based
NCAV (Graham) 809.20 KRW 1,084 KRW 1,618 KRW 50

Widest divergence: Multiples (1,376 KRW) versus Asset-Based (1,084 KRW). Highest evidence: P/B Multiple (55).

Notify me when 322510 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 3.3B KRW
Revenue growth (YoY) -15.1%
Return on equity -33.5%
Free cash flow −12.7B KRW FY2025
Operating margin -820%
Net debt 26.2B KRW FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 27/100

Of which business quality 29 · Market factors (momentum, volatility) 20

Profitability 2
Margins and returns on capital today
Quality Growth 78
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 41
Balance sheet, leverage, solvency risk
Investment 19
Disciplined investing over empire-building
Low Volatility 22
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 28
Distance to the 52-week high (market factor)
Net Issuance 40
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

JLK, Inc. provides diagnosis support to the patients with its AI-driven medical platform in South Korea. The company offers AI medical and AI security solutions. Its AI platform provides on-site/real-time service that is connected to various systems built in the hospital and enables the professional needs of physicians to diagnose diseases.

Full company description

JLK, Inc. provides diagnosis support to the patients with its AI-driven medical platform in South Korea. The company offers AI medical and AI security solutions. Its AI platform provides on-site/real-time service that is connected to various systems built in the hospital and enables the professional needs of physicians to diagnose diseases. The company provides medical management, medical treatment, and medical service in brain diseases, such as ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer's disease; and in lung diseases, coronary artery disease, prostate cancer, and digital pathology. JLK, Inc. was formerly known as JLK INSPECTION Co.,Ltd. JLK, Inc. was incorporated in 2014 and is based in Cheongju-si, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

JLK, Inc reported revenue of 3.3B KRW in FY2025 versus 3.8B KRW in FY2021, a compound −3.1%/yr. Reported net income was −13.6B KRW in FY2025.

Growth Quality 6/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
3.3B KRW
Latest YoY
+133.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−5.7%
Avg. growth/yr (8Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+58.4%
Revenue −3.1%/yr
FY21 3.8B KRW
FY22 3.4B KRW
FY23 2.5B KRW
FY24 1.4B KRW
FY25 3.3B KRW
Net income
FY21 −7.6B KRW
FY22 −9.0B KRW
FY23 −7.3B KRW
FY24 −13.5B KRW
FY25 −13.6B KRW

322510 screens 75% overvalued. Compare with ITOCHU Corporation →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "JLK, Inc Fair Value". https://www.fairvalue-calculator.com/stock/322510

Peer Group

Conglomerates · 385 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 29 · Bottom 25%
Fair Value upside −75% · Bottom 25%
Return on assets -11% · Bottom 25%
Net margin (TTM) 0% · Below median
Revenue growth -15% · Bottom 25%
Debt / equity 0.19× · Lower than median

Valuation Multiples vs Conglomerates median · lower = cheaper

P/S (TTM) 0.03× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 27
FUTURE 0 · sector 17
PAST 0 · sector 18
HEALTH 90 · sector 89
DIVIDEND 0 · sector 39

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Conglomerates stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
ITOCHU Corporation ITOCHU19 7.20 THB 14.40 THB +100%
SK Inc 034730 553,000 KRW 615,077 KRW +11%
PT Astra International Tbk, ASII 4,860 IDR 9,720 IDR +100%
Koç Holding KCHOL 205.80 TRY 182.26 TRY -11%
SRF Limited SRF ₹2,585 ₹859.71 -67%
Empresas Copec S.A COPEC 6,030 CLP 10,809 CLP +79%
Posco International Corporation 047050 54,300 KRW 71,119 KRW +31%
Tube Investments of India Limited TIINDIA ₹2,839 ₹723.80 -75%
Doosan Corporation 000155 436,000 KRW 93,413 KRW -79%
Thermax Limited THERMAX ₹4,002 ₹1,343 -66%

Compare JLK, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is JLK, Inc (322510) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 1,370 KRW versus a price of 5,500 KRW, about −75% (overvalued).
What is the fair value of 322510?
Our model-based fair value for JLK, Inc is 1,370 KRW (as of Aug 13, 2026), built from audited fundamentals. The current price is 5,500 KRW.
What is the quality score of 322510?
JLK, Inc has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of JLK, Inc (322510)?
JLK, Inc reported trailing-twelve-month revenue of about 3.3B KRW (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 322510?
The net profit margin of JLK, Inc is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track JLK, Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.